

GLAXOSMITHKLINE PLC
Form 6-K
February 19, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 19 February 2019

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial Notification
 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

 - a) Description of the financial instrument ISIN: GB0009252882
 - b) Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£0.0000	32,596 (Deferred)
£0.0000	19,234 (Matching)
- Aggregated information
- d) Aggregated volume 51,830
 - Price £0.0000
 - e) Date of the transaction 2019-02-18
 - f) Place of the transaction n/a

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.756	15,345 (Deferred)
£15.756	9,053 (Matching)

Aggregated information

- d) Aggregated volume 24,398
- Price £15.756
- e) Date of the transaction 2019-02-18
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R Connor
 - b) Position/status President, Global Vaccines
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Ordinary shares of 25 pence
each ('Ordinary Shares')

a)	Description of the financial instrument	ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)	Price(s) Volume(s)
		£0.0000 11,073 (Deferred)
		£0.0000 6,534 (Matching)
	Aggregated information	
d)	Aggregated volume	17,607
	Price	£0.0000
e)	Date of the transaction	2019-02-18
f)	Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr R Connor
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')

a)	Description of the financial instrument	ISIN: GB0009252882
----	---	--------------------

b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over
----	---------------------------	--

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Ordinary Shares exercised on
18 February 2019 under the
Company's Deferred Annual
Bonus Plan - Deferred Bonus
and Matching Awards.

Price(s) Volume(s)
c) Price(s) and volume(s) £15.756 5,218 (Deferred)
£15.756 3,079 (Matching)

Aggregated information

d) Aggregated volume 8,297
Price £15.756
e) Date of the transaction 2019-02-18
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans
b) Position/status Chief Financial Officer
c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction The exercise of nil-cost
options over Ordinary Shares
granted on 11 February 2016
under the Company's 2009
Deferred Annual Bonus Plan -
Deferred Bonus and Matching
Awards.

Price(s) Volume(s)
c) Price(s) and volume(s) £0.0000 43,044 (Deferred)
£0.0000 25,398 (Matching)

Aggregated information

d) Aggregated volume 68,442
Price £0.0000

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2019-02-18
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans
 b) Position/status Chief Financial Officer
 c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c) Price(s) and volume(s)

Price(s) Volume(s)
 £15.716 20,263 (Deferred)
 £15.716 11,955 (Matching)

Aggregated information

- d) Aggregated volume 32,218
 Price £15.716
 e) Date of the transaction 2019-02-18
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P Thomson

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, Global Affairs
 c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
- | Price(s) | Volume(s) |
|----------|------------------|
| £0.0000 | 9,064 (Deferred) |
| £0.0000 | 5,349 (Matching) |
- c) Price(s) and volume(s)

- Aggregated information
- d) Aggregated volume 14,413
 Price £0.0000
- e) Date of the transaction 2019-02-18
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr P Thomson
 b) Position/status President, Global Affairs
 c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7215	4,271 (Deferred)
	£15.7215	2,521 (Matching)

Aggregated information	
d) Aggregated volume	6,792
Price	£15.7215
e) Date of the transaction	2019-02-18
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 19, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc